Advertisement

Home / Business / Eli Lilly inks voluntary licensing agreements with three Indian pharmaceutical firms

Eli Lilly inks voluntary licensing agreements with three Indian pharmaceutical firms

The company is also in discussions with several other manufacturers for the potential grant of additional voluntary licences
Representational image.

Our Special Correspondent   |   Mumbai   |   Published 11.05.21, 12:42 AM

Eli Lilly and Company on Monday said it has inked voluntary licensing agreements with three Indian pharmaceutical firms — Sun Pharma, Cipla and Lupin — to expedite the availability of its arthritis drug Baricitinib for the treatment of Covid-19 patients in the country.

The company “has issued royalty-free, non-exclusive voluntary licences to the three firms, which are collaborating with Lilly to accelerate and expand the availability of Baricitinib in India”, Eli Lilly said.

Advertisement

The company is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licences.

Baricitinib is used in combination with Remdesivir to treat Covid-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. 



Advertisement
Advertisement
Mobile Article Page Banner
Advertisement
 
 
 
Copyright © 2020 The Telegraph. All rights reserved.